PATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY

System, Test, Her-2/neu, Ihc

FDA Premarket Approval P990081 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for modifications to the pathway c-erbb-2 primary antibody(clone cb11) which include 1) change the primary antibody from the mouse monoclonal antibody cb11 to the rabbit monoclonal antibody 4b5, 2) change the detection format from basic dab detection kit to the ventana medical systems iview dab detection kit, 3) add the optional ultraview universal dab detection kit for biotin free detection format, 4) consolidate level 1,3 and negative her-2 assay control slides onto a single slide and add a level 2 assay control and the control will be marketed under the trade name of pathway her2 4 in 1 control slide, and 5) include the ventana image analysis system (vias) in the labeling. The device, as modified, will be marketed under the trade name pathway anti-her-2/neu (4b5) primary antibody and is indicated for: ventana medical systems, inc.? S (ventana) pathway anti-her-2/neu (4b5) primary antibody (pathway her2 (4b5)) is a rabbit monoclonal antibody intended for laboratory use for the semi-quantitative detection of her2 antigen in sections of formalin-fixed, paraffin-embedded normal and neoplastic tissue on a ventana automated immunohistochemistry slide staining device. It is indicated as an aid in the assessment of breast cancer patients for whom herceptin treatment is being considered.

DevicePATHWAY ANTI-HER-2/NEU (4B5) PRIMARY ANTIBODY
Classification NameSystem, Test, Her-2/neu, Ihc
Generic NameSystem, Test, Her-2/neu, Ihc
ApplicantVENTANA MEDICAL SYSTEMS, INC.
Date Received2006-05-04
Decision Date2007-01-11
PMAP990081
SupplementS003
Product CodeMVC
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address VENTANA MEDICAL SYSTEMS, INC. 1910 E. Innovation Park Dr. tucson, AZ 85755

Supplemental Filings

Supplement NumberDateSupplement Type
P990081Original Filing
S050 2022-10-14 30-day Notice
S049
S048 2022-07-12 30-day Notice
S047
S046 2022-02-16 Special (immediate Track)
S045 2022-01-28 135 Review Track For 30-day Notice
S044 2021-02-22 Real-time Process
S043 2020-08-26 Real-time Process
S042 2020-01-13 Real-time Process
S041 2019-08-22 Real-time Process
S040 2019-04-09 30-day Notice
S039 2019-02-13 Normal 180 Day Track
S038 2018-06-18 Real-time Process
S037
S036
S035 2016-11-15 Normal 180 Day Track
S034 2015-12-10 135 Review Track For 30-day Notice
S033 2015-08-26 30-day Notice
S032 2015-08-14 30-day Notice
S031 2014-10-27 30-day Notice
S030 2014-06-16 135 Review Track For 30-day Notice
S029 2014-02-14 Normal 180 Day Track
S028 2014-02-06 Real-time Process
S027 2014-01-22 Real-time Process
S026 2014-01-06 30-day Notice
S025 2013-12-27 30-day Notice
S024 2013-11-12 30-day Notice
S023 2013-10-28 30-day Notice
S022 2013-08-30 30-day Notice
S021 2013-07-30 30-day Notice
S020 2013-05-07 135 Review Track For 30-day Notice
S019 2013-05-06 Real-time Process
S018 2013-04-17 30-day Notice
S017 2013-03-12 Real-time Process
S016 2013-03-04 30-day Notice
S015 2013-01-14 Real-time Process
S014 2012-08-31 Real-time Process
S013 2012-07-27 30-day Notice
S012 2012-07-25 Real-time Process
S011 2011-05-23 Normal 180 Day Track
S010 2011-01-03 Normal 180 Day Track
S009
S008 2010-10-21 Special (immediate Track)
S007 2007-11-19 30-day Notice
S006 2007-06-27 30-day Notice
S005 2007-03-02 Special (immediate Track)
S004 2006-08-28 30-day Notice
S003 2006-05-04 Normal 180 Day Track
S002 2005-09-06 Real-time Process
S001 2002-08-20 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.